RxDoctor Payments Data

Louis Teodori, DO

Neurology · Merrillville, INNPI 1487699880

Payments from drug & device makers

$7,629in general payments, 2019–2025

Across 415 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$541
  • Novartis$510
  • UCB, Inc.$445
  • Pfizer$353
  • AstraZeneca$297
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$491%
  • Food & beverage$7,56399%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)86$1,229
Lilly USA, LLC23$541
Novartis29$510
UCB, Inc.25$445
Pfizer21$353
AstraZeneca(2 entities)16$297
Teva Pharmaceuticals USA, Inc.11$248
Eisai Inc.12$245
SK Life Science, Inc.10$223
Neurocrine Biosciences, Inc.11$205
Takeda Pharmaceuticals U.S.A., Inc.7$189
Acorda Therapeutics, Inc12$184
Amgen10$179
Amneal Pharmaceuticals LLC8$164
Silk Road Medical, Inc.1$150
Sanofi8$139
Supernus Pharmaceuticals, Inc.7$131
Argenx US, Inc.6$130
Catalyst Pharmaceuticals, Inc.6$122
Sunovion Pharmaceuticals Inc.9$119
Livanova USA, Inc.6$116
Acadia Pharmaceuticals Inc6$111
Lundbeck LLC5$111
Johnson & Johnson7$100
Upsher-smith Laboratories LLC5$97
MDD US Operations, LLC6$95
CSL Behring6$95
Otsuka America Pharmaceutical, Inc.4$85
Banner Life Sciences, LLC3$68
EMD Serono, Inc.4$67
Biogen4$59
Biohaven Pharmaceuticals, Inc.3$52
Corium, LLC2$47
Corcept Therapeutics2$47
Biohaven Pharmaceutical Holding Company Ltd.3$45
Merz Pharmaceuticals, LLC2$45
Scilex Pharmaceuticals Inc.2$44
Cycle Pharmaceuticals Inc2$41
Genentech USA, Inc.2$41
Boehringer Ingelheim2$37
Organogenesis Inc.1$33
Neurelis, Inc.1$33
Sumitomo Pharma America, Inc.2$31
Axsome Therapeutics, Inc.1$29
Ceribell, Inc.1$28
ANI Pharmaceuticals, Inc.1$27
Tanabe Pharma America, Inc.1$24
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$23
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
Exact Sciences1$18
Phathom Pharmaceuticals, Inc.1$18
Astellas Pharma US Inc1$17
Adamas Pharmaceuticals, Inc.1$16
Abbott1$16
Boston Scientific1$16
Alnylam Pharmaceuticals Inc.1$16
Merck1$15
Avanir Pharmaceuticals, Inc.1$14
Azurity Pharmaceuticals, Inc.1$14
Impel Pharmaceuticals Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,629 in reported general payments places this provider in the 65th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$253,684
Medicare patients
907
Services billed
8,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b14$154,631
Aimovig AutoinjectorErenumab-Aooe191$149,650
Nurtec OdtRimegepant Sulfate119$123,661
IngrezzaValbenazine Tosylate11$91,344
Emgality PenGalcanezumab-Gnlm68$53,127
UbrelvyUbrogepant52$51,855
BriviactBrivaracetam28$39,295
FycompaPerampanel18$26,454
AptiomEslicarbazepine Acetate18$22,408
Ajovy AutoinjectorFremanezumab-Vfrm15$17,195
NamzaricMemantine Hcl/Donepezil Hcl23$16,924
NuedextaDextromethorphan Hbr/Quinidine15$16,810
MestinonPyridostigmine Bromide13$14,707
Memantine Hcl402$12,593
Gabapentin389$11,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$353$123,661119 claims
Neurocrine Biosciences, Inc.Ingrezza$205$91,34411 claims
AbbVieUbrelvy, Namzaric$1,229$68,77975 claims
UCB, Inc.Briviact$445$39,29528 claims
Eisai Inc.Fycompa$245$26,45418 claims
Sunovion Pharmaceuticals Inc.Aptiom$119$22,40818 claims
Avanir Pharmaceuticals, Inc.Nuedexta$14$16,81015 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$164$4,60947 claims
Lilly USA, LLCOlanzapine$541$4,177102 claims
Upsher-smith Laboratories LLCTopiramate$97$2,888213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 neurology providers in Indiana.

Other neurology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →